Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy

Reuters

10/23

Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy

Medtronic plc has announced new clinical milestones spanning its coronary, renal denervation, and structural heart businesses, with several key data presentations scheduled for the upcoming 37th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The company will present new evidence on the real-world usage of the Prevail™ Drug-Coated Balloon in complex coronary artery lesion populations, including diabetic patients. Additionally, final global results from the Optimize PRO Study, involving 653 patients across 50 centers, will highlight outcomes in transcatheter aortic valve replacement procedures. In the renal denervation segment, Medtronic will report final three-year results from the SPYRAL HTN-ON MED randomized study, assessing the durability of blood pressure reductions using the Symplicity Spyral™ renal denervation system in patients on antihypertensive medications. The first results from the SPYRAL AFFIRM study will also be presented, evaluating the impact of renal denervation on blood pressure in a large cohort of high cardiovascular risk patients in the US. These results are scheduled to be presented during the TCT symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577030200"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577030200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577030200?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577030200","market":"us","top_or_hot":-1,"title":"Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Medtronic plc has announced new clinical milestones spanning its coronary, renal denervation, and structural heart businesses, with several key data presentations scheduled for the upcoming 37th Transcatheter Cardiovascular <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TCT) scientific symposium. The company will present new evidence on the real-world usage of the Prevail™ Drug-Coated Balloon in complex coronary artery lesion populations, including diabetic patients. Additionally, final global results from the Optimize PRO Study, involving 653 patients across 50 centers, will highlight outcomes in transcatheter aortic valve replacement procedures. In the renal denervation segment, Medtronic will report final three-year results from the SPYRAL HTN-ON MED randomized study, assessing the durability of blood pressure reductions using the Symplicity Spyral™ renal denervation system in patients on antihypertensive medications. The first results from the SPYRAL AFFIRM study will also be presented, evaluating the impact of renal denervation on blood pressure in a large cohort of high cardiovascular risk patients in the US. These results are scheduled to be presented during the TCT symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-23 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Medtronic plc has announced new clinical milestones spanning its coronary, renal denervation, and structural heart businesses, with several key data presentations scheduled for the upcoming 37th Transcatheter Cardiovascular <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TCT) scientific symposium. The company will present new evidence on the real-world usage of the Prevail™ Drug-Coated Balloon in complex coronary artery lesion populations, including diabetic patients. Additionally, final global results from the Optimize PRO Study, involving 653 patients across 50 centers, will highlight outcomes in transcatheter aortic valve replacement procedures. In the renal denervation segment, Medtronic will report final three-year results from the SPYRAL HTN-ON MED randomized study, assessing the durability of blood pressure reductions using the Symplicity Spyral™ renal denervation system in patients on antihypertensive medications. The first results from the SPYRAL AFFIRM study will also be presented, evaluating the impact of renal denervation on blood pressure in a large cohort of high cardiovascular risk patients in the US. These results are scheduled to be presented during the TCT symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0496365809.HKD","symbol_name":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDLhGDQ7:1","article_id":"2577030200","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577030200","pubTimestamp":1761224919,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medtronic plc has announced new clinical milestones spanning its coronary, renal denervation, and structural heart businesses, with several key data presentations scheduled for the upcoming 37th Transcatheter Cardiovascular Therapeutics  scientific symposium. The company will present new evidence on the real-world usage of the Prevail Drug-Coated Balloon in complex coronary artery lesion populations, including diabetic patients. Additionally, final global results from the Optimize PRO Study, involving 653 patients across 50 centers, will highlight outcomes in transcatheter aortic valve replacement procedures. In the renal denervation segment, Medtronic will report final three-year results from the SPYRAL HTN-ON MED randomized study, assessing the durability of blood pressure reductions using the Symplicity Spyral renal denervation system in patients on antihypertensive medications. The first results from the SPYRAL AFFIRM study will also be presented, evaluating the impact of renal den","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","BK4082":"医疗保健设备","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4588":"碎股","MDT":"美敦力","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC"},"translate_title":"美敦力公布为期三年的SPYRAL HTN-ON MED肾去神经疗效试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":0.9},"content_text":"Medtronic Unveils Three-Year SPYRAL HTN-ON MED Trial Results on Renal Denervation Efficacy\n    \n\n        Medtronic plc has announced new clinical milestones spanning its coronary, renal denervation, and structural heart businesses, with several key data presentations scheduled for the upcoming 37th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The company will present new evidence on the real-world usage of the Prevail™ Drug-Coated Balloon in complex coronary artery lesion populations, including diabetic patients. Additionally, final global results from the Optimize PRO Study, involving 653 patients across 50 centers, will highlight outcomes in transcatheter aortic valve replacement procedures. In the renal denervation segment, Medtronic will report final three-year results from the SPYRAL HTN-ON MED randomized study, assessing the durability of blood pressure reductions using the Symplicity Spyral™ renal denervation system in patients on antihypertensive medications. The first results from the SPYRAL AFFIRM study will also be presented, evaluating the impact of renal denervation on blood pressure in a large cohort of high cardiovascular risk patients in the US. These results are scheduled to be presented during the TCT symposium.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}